SPY382.33-9.44 -2.41%
DIA313.98-5.55 -1.74%
IXIC13,119.43-478.54 -3.52%

DJ J&J Submits Application For Its COVID-19 Shot To The FDA -- MarketWatch

· 02/04/2021 17:57
For more from MarketWatch: http://www.marketwatch.com/newsviewer

Shares of Johnson & Johnson (JNJ) gained 1.2% in after-hours trading on Thursday after the company announced that it had submitted an application for an emergency use authorization to the Food and Drug Administration for its COVID-19 vaccine candidate. The experimental single-dose COVID vaccine was 72% effective (http://www.marketwatch.com/story/johnson-johnson-says-covid-vaccine-was-66-effective-in-phase-3-trial-2021-01-29) at preventing symptomatic disease in the U.S. arm of the Phase 3 clinical trial, according to findings released Jan. 29. The FDA is expected to schedule a meeting of an advisory committee that will vote on whether the benefits of the vaccine outweigh the risks, as was done prior to the emergency use authorizations of BioNTech SE (BNTX)/Pfizer Inc. (PFE) and Moderna Inc.'s (MRNA) COVID-19 vaccines. The company also said Thursday that its vaccine can be stored for two years at negative four degrees Fahrenheit in most standard refrigerators, and that it can provide 100 million doses of its vaccine candidate in the U.S. in the first half of 2021. J&J's stock has gained 6.8% over the past 12 months, while the broader S&P 500 is up 17.9%.

-Jaimy Lee

(END) Dow Jones Newswires

February 04, 2021 17:57 ET (22:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.